Poliovirus To Treat Brain Cancer: A Curious Chronology - DNA Science
Promising brain cancer trial given breakthrough status by FDA - CBS News
Preston Robert Tisch Brain Tumor Center | Duke Cancer Institute
Duke's Poliovirus Therapy Wins “Breakthrough” Status | The Preston Robert Tisch Brain Tumor Center
Clinical Trial Studies Treating Brain Tumor with Genetically Modified Poliovirus | University Hospitals
Duke Researchers Uncover Pathway in Lung Cancer Brain Metastasis | Duke Health
Poliovirus Therapy for Glioblastoma has Three-Year Survival Rate of 21 Percent | Duke Today
Clinical Trials | The Preston Robert Tisch Brain Tumor Center
Brain immunology and immunotherapy in brain tumours | Nature Reviews Cancer
glioblastoma | Duke Cancer Institute
The Preston Robert Tisch Brain Tumor Center
Glioblastoma: New tools against brain cancer - CBS News
New clues toward treating pediatric brain tumors harboring epigenetic mutation
Duke Clinical & Translational Science Institute
Frontiers | Tumor-Specific T Cell Activation in Malignant Brain Tumors | Immunology
Cancer breakthrough: Duke clinical trial destroys SC woman's brain tumor
Killing Cancer: 60 Minutes follows brain cancer patients in clinical trial that kills cancer cells | Private Diagnostic Clinic
Chemo for glioblastoma may work better in morning than evening – Washington University School of Medicine in St. Louis
Frontiers | Primary Brain Tumor Research Productivity in Southeast Asia and Its Association With Socioeconomic Determinants and Burden of Disease | Oncology
Poliovirus Therapy Shows Potential as Cancer Vaccine in Lab Studies | Duke Health
Poliovirus Therapy for Glioblastoma has Three-Year Survival Rate of 21 Percent | Duke Today
How the polio virus is being used to combat brain cancer | CNN
Cancer breakthrough: Duke clinical trial destroys SC woman's brain tumor
Poliovirus Therapy Shows Early Promise for Treating Aggressive Brain Cancer, but Questions Linger - Scientific American
Poliovirus treatment for glioblastoma posts 'encouraging' survival data, but work remains | FierceBiotech
